Literature DB >> 8484698

Adjuvant oestrogen treatment increases bone mineral density in postmenopausal women with rheumatoid arthritis.

H R van den Brink1, W F Lems, A A van Everdingen, J W Bijlsma.   

Abstract

OBJECTIVES: The beneficial effect of oestrogens on bone mineral density in women with osteoporosis is well known. Patients with rheumatoid arthritis (RA) are at risk for osteoporosis. A study was therefore set up to investigate the effects of adjuvant oestrogen treatment on bone metabolism and bone mineral density in postmenopausal women with RA.
METHODS: Forty postmenopausal women with active RA were admitted to a placebo controlled, double blind study investigating the beneficial effect of adjuvant oestradiols or placebo on bone metabolism and bone mineral density. Thirty three patients completed 52 weeks of treatment.
RESULTS: At the start both treatment groups were comparable for all parameters. In the oestrogen group serum concentrations of osteocalcin decreased and concentrations of sex hormone binding globulin increased during the study. Bone mineral density measured by dual energy x ray absorptiometry increased significantly in the lumbar vertebral spine and femoral neck in the oestrogen group compared with the placebo group.
CONCLUSIONS: This study shows that the use of adjuvant oestrogens in post-menopausal women with active RA increases bone mineral density.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8484698      PMCID: PMC1005630          DOI: 10.1136/ard.52.4.302

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  13 in total

1.  Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis.

Authors:  T Storm; G Thamsborg; T Steiniche; H K Genant; O H Sørensen
Journal:  N Engl J Med       Date:  1990-05-03       Impact factor: 91.245

Review 2.  Bone metabolism in patients with rheumatoid arthritis.

Authors:  J W Bijlsma
Journal:  Clin Rheumatol       Date:  1988-03       Impact factor: 2.980

3.  Fractures after rheumatoid arthritis. A population-based study.

Authors:  J R Hooyman; L J Melton; A M Nelson; W M O'Fallon; B L Riggs
Journal:  Arthritis Rheum       Date:  1984-12

4.  Long-term calcitonin therapy in postmenopausal osteoporosis.

Authors:  H E Gruber; J L Ivey; D J Baylink; M Matthews; W B Nelp; K Sisom; C H Chesnut
Journal:  Metabolism       Date:  1984-04       Impact factor: 8.694

5.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

Authors:  F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra
Journal:  Arthritis Rheum       Date:  1988-03

6.  Long-term estrogen replacement therapy prevents bone loss and fractures.

Authors:  B Ettinger; H K Genant; C E Cann
Journal:  Ann Intern Med       Date:  1985-03       Impact factor: 25.391

7.  Determinants of axial bone loss in rheumatoid arthritis.

Authors:  P N Sambrook; J A Eisman; G D Champion; M G Yeates; N A Pocock; S Eberl
Journal:  Arthritis Rheum       Date:  1987-07

8.  Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study.

Authors:  D P Kiel; D T Felson; J J Anderson; P W Wilson; M A Moskowitz
Journal:  N Engl J Med       Date:  1987-11-05       Impact factor: 91.245

9.  Bone metabolism in rheumatoid arthritis compared with postmenopausal osteoporosis.

Authors:  R M van Soesbergen; P Lips; A van den Ende; J K van der Korst
Journal:  Ann Rheum Dis       Date:  1986-02       Impact factor: 19.103

10.  Sex hormone status and osteoporosis in postmenopausal women with rheumatoid arthritis.

Authors:  P N Sambrook; J A Eisman; G D Champion; N A Pocock
Journal:  Arthritis Rheum       Date:  1988-08
View more
  11 in total

1.  Should we look for osteoporosis in patients with rheumatoid arthritis?

Authors:  W F Lems; B A Dijkmans
Journal:  Ann Rheum Dis       Date:  1998-06       Impact factor: 19.103

2.  Effect of hormone replacement therapy on markers of bone metabolism in RA.

Authors:  W F Lems; H R van den Brink; M I Gerrits; H J van Rijn; J W Bijlsma
Journal:  Ann Rheum Dis       Date:  1993-11       Impact factor: 19.103

3.  Long term follow up of spinal trabecular bone mineral density in women with non-steroid treated rheumatoid arthritis.

Authors:  A M Cooper; M M O'Sullivan; D Clements; J E Compston; W D Evans; C Evans
Journal:  Ann Rheum Dis       Date:  1994-02       Impact factor: 19.103

4.  Androgens as adjuvant treatment in postmenopausal female patients with rheumatoid arthritis.

Authors:  A Booji; C M Biewenga-Booji; O Huber-Bruning; C Cornelis; J W Jacobs; J W Bijlsma
Journal:  Ann Rheum Dis       Date:  1996-11       Impact factor: 19.103

5.  Effects of hormone replacement therapy in rheumatoid arthritis: a double blind placebo-controlled study.

Authors:  A G MacDonald; E A Murphy; H A Capell; U Z Bankowska; S H Ralston
Journal:  Ann Rheum Dis       Date:  1994-01       Impact factor: 19.103

6.  Adjuvant oestrogen therapy does not improve disease activity in postmenopausal patients with rheumatoid arthritis.

Authors:  H R van den Brink; A A van Everdingen; M J van Wijk; J W Jacobs; J W Bijlsma
Journal:  Ann Rheum Dis       Date:  1993-12       Impact factor: 19.103

7.  A randomised controlled trial of the effect of hormone replacement therapy on disease activity in postmenopausal rheumatoid arthritis.

Authors:  G M Hall; M Daniels; E C Huskisson; T D Spector
Journal:  Ann Rheum Dis       Date:  1994-02       Impact factor: 19.103

8.  Loss of bone mineral density in premenopausal women with systemic lupus erythematosus.

Authors:  F Formiga; I Moga; J M Nolla; M Pac; F Mitjavila; D Roig-Escofet
Journal:  Ann Rheum Dis       Date:  1995-04       Impact factor: 19.103

9.  Hormone replacement therapy in chronic active hepatitis; a case report.

Authors:  D Clements; J Rhodes
Journal:  Gut       Date:  1993-11       Impact factor: 23.059

10.  Evaluation of a model for post-partum arthritis and the role of oestrogen in prevention of MRL-lpr associated rheumatic conditions.

Authors:  L G Ratkay; D Zhang; J Tonzetich; J G Levy; J D Waterfield
Journal:  Clin Exp Immunol       Date:  1994-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.